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Abstract
Background: Canine	anti‐mouse	antibodies	are	a	potential	source	of	 immunoassay	
interference,	but	erroneous	immunoassay	results	are	not	always	easily	identifiable.	
Anti‐Müllerian	hormone	(AMH)	is	a	marker	for	the	presence	of	gonads	in	dogs,	but	
elevated	AMH	concentrations	in	neutered	dogs	could	also	be	caused	by	antibody	in‐
terference.	For	other	assays,	a	discrepant	result	obtained	after	antibody	precipitation	
might	indicate	antibody	interference.
Objectives: We	aimed	 to	evaluate	 if	 canine	anti‐mouse	antibodies	are	a	source	of	
erroneous	results	in	the	AMH	assay	and	if	antibody	precipitation	with	polyethylene	
glycol	(PEG)	is	a	useful	tool	for	detecting	antibody	interference	in	a	variety	of	immu‐
noassays	used	in	the	veterinary	clinical	laboratory.
Methods: Twenty‐nine	 positive	 and	 25	 negative	 samples	 for	 anti‐mouse	 antibod‐
ies	were	analyzed	for	AMH,	canine	total	thyroxine	 (TT4),	canine	thyroid‐stimulating	
hormone	(TSH),	and	progesterone	before	and	after	treatment	with	PEG.	Results	that	
differed	by	more	than	four	SDs	from	the	intra‐assay	coefficients	of	variation	were	con‐
sidered	discrepant.	Elevated	AMH	concentrations	in	neutered	dogs	with	anti‐mouse	
antibodies	and	no	visible	gonads	present	were	considered	evidence	of	interference.
Results: Evidence	of	antibody	interference	was	found	in	two	samples	analyzed	for	
AMH.	The	presence	of	 anti‐mouse	 antibodies	did	not	 lead	 to	 a	higher	proportion	
of	discrepant	results	after	PEG	treatment	for	any	of	the	immunoassays.	The	overall	
incidence	of	discrepant	results	for	healthy	controls	was	very	high	(73%).
Conclusions: Canine	anti‐mouse	antibodies	are	a	source	of	erroneous	AMH	results.	
Antibody	precipitation	with	PEG	is	not	a	useful	tool	for	detecting	interference	caused	
by	such	antibodies.
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1  | INTRODUC TION
Since	 the	 invention	of	 the	 radioimmunoassay	 in	 the	1950s,	 immu‐
noassays	have	become	the	standard	methods	 for	 the	detection	of	
many	clinically	important	proteins	and	peptides.	Without	immuno‐
assays,	 the	diagnosing	many	medical	 conditions	 and	being	 able	 to	
monitor	these	medical	conditions	at	follow‐up	visits	would	be	seri‐
ously	affected.	However,	despite	several	years	of	advancements	in	
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immunoassay	development,	there	are	still	some	limitations.	One	par‐
ticularly	striking	flaw	inherent	to	immunoassays	is	the	risk	of	inter‐
ference	from	endogenous	antibodies	 in	patient	serum	and	plasma.	
By	emulating	the	actions	of	the	analyte	of	interest,	these	antibodies	
can	 cause	 false‐positive	 results.	 Immunoassay	manufacturers	 rou‐
tinely	include	warnings	about	interfering	“heterophilic	antibodies”	or	
“HAMAs”	(human	anti‐mouse	antibodies)	in	package	inserts.	In	prac‐
tice,	this	information	will	usually	not	reach	the	veterinary	clinician,	
or	could	simply	be	dismissed,	perhaps	because	such	antibodies	are	
perceived	to	be	very	rare	or	absent	in	animals.	We	have	developed	
a	species‐independent	assay	detecting	endogenous	anti‐mouse	an‐
tibodies	and	estimated	a	prevalence	of	9%	in	dogs	and	5%	in	cats.1
The	 suspicion	 of	 immunoassay	 interference	 could	 be	 raised	
when	test	results	are	discordant	with	the	clinical	presentation	of	the	
patient.	An	 increase	marker	measurement	 for	 no	 apparent	 reason	
could	also	indicate	interference.	If	the	measurement	has	a	high	im‐
pact	on	the	course	of	treatment,	there	is	an	obvious	risk	for	misdi‐
agnosis	and	inappropriate	therapy.	For	instance,	the	anti‐Müllerian	
hormone	(AMH)	assay	is	routinely	used	to	determine	the	presence	
of	gonads	in	cats	and	dogs.2‐5	Interference	in	this	assay	could	lead	
to	unnecessary	surgery	if	patients	are	incorrectly	determined	to	be	
unneutered.	There	have	been	reports	of	potentially	erroneous	AMH	
results	in	this	assay	since	it	was	first	evaluated	in	canine	samples,2,6,7 
and	antibody	interference	has	previously	been	described	in	people.8
The	 presence	 of	 discrepant	 results	 after	 various	 sample	 treat‐
ments	 is	 another	 hallmark	 of	 interference.	 Serial	 dilutions	 are	
sometimes	 recommended	 to	 investigate	 interference,	 based	 on	
the	premise	that	samples	with	 interfering	antibodies	will	generally	
display	nonlinearity	in	dilutions.	However,	the	method	has	been	re‐
ported	to	have	poor	sensitivity	with	a	false‐negative	rate	of	40%,9 
and	 false‐positive	 results	 are	 likely	 if	 heterogeneous	 analytes	 are	
being	 investigated.10	 Blocking	 of	 interfering	 antibodies	 with	 non‐
specific	 immunoglobulins	 (Igs)	 is	another	method,	but	the	blocking	
agents	have	to	be	adapted	to	the	specific	immunoassay	to	maximize	
the	chance	of	success.	An	alternative	approach	to	tackle	 immuno‐
assay	 interference	 is	 to	deplete	 the	samples	of	 Igs	by	 treating	 the	
samples	with	a	precipitant,	such	as	polyethylene	glycol	 (PEG).	PEG	
lowers	the	solubility	of	Igs	and	has	been	reported	to	precipitate	both	
serum	 IgG	 and	 IgM	efficiently.11,12	A	 sample	 treatment	 procedure	
with	PEG	is	quickly	performed,	and	feasible	to	implement	into	nor‐
mal	laboratory	routines.	The	present	study	aimed	to	evaluate	if	anti‐
mouse	 antibodies	 detected	 in	 a	 species‐independent	 interference	
assay	are	a	source	of	erroneous	results	in	the	AMH	assay	and	if	PEG	
treatment	is	a	useful	tool	for	detecting	antibody	interference	in	a	va‐
riety	of	commercial	immunoassays	used	in	the	veterinary	laboratory.
2  | MATERIAL S AND METHODS
2.1 | Samples
Serum	that	had	tested	positive	for	anti‐mouse	antibodies	 in	a	pre‐
vious	screening	study	were	used,1	no	other	 inclusion	criteria	were	
applied.	Serum	was	frozen	and	stored	at	−20°C	for	up	to	18	months	
until	 analysis.	 All	 samples	were	 thawed	 at	 room	 temperature	 (RT)	
and	 thoroughly	 vortexed	 before	 analysis.	 Exclusion	 criteria	 were	
clearly	visible	signs	of	hemolysis,	bilirubinemia,	or	lipemia.
Control	 sera	were	 collected	 from	 the	 routine	 laboratory	 anal‐
ysis	of	progesterone	at	 the	University	Animal	Hospital	 in	Uppsala,	
Sweden,	 and	 from	 a	 sampling	 of	 staff‐owned	 dogs.	 Serum	 was	
frozen	 and	 stored	 at	 −20°C	 for	 up	 to	 3	months	 until	 analysis.	 All	
samples	were	 thawed	at	RT	and	 thoroughly	vortexed	before	anal‐
ysis.	 Inclusion	criteria	for	control	dogs	were	a	negative	anti‐mouse	
antibody	 test	 1	 and	clinically	healthy	according	 to	medical	 records	
and	personal	communications	with	owners.	Exclusion	criteria	were	
clearly	visible	signs	of	hemolysis,	bilirubinemia,	or	lipemia.
2.2 | Ethical considerations
The	 study	 was	 approved	 by	 the	 Uppsala	 Ethical	 Committee	 of	
Animal	 Experimentation	 (C	 136/13).	 In	 accordance	 with	 Swedish	
animal	 welfare	 regulations	 (SJVFS	 2015:38),	 written	 consent	 was	
obtained	from	all	dog	owners.
2.3 | Immunoassays
For	evaluating	the	effect	of	anti‐mouse	antibodies	on	AMH	concen‐
trations,	a	sandwich	ELISA	(AMH	Gen	II,	Beckman	Coulter,	A79765)	
was	used.
For	the	PEG	screening,	a	panel	of	immunoassays	was	selected	
for	inclusion;	AMH	Gen	II,	progesterone,	canine	thyroid‐stimulat‐
ing	hormone	 (TSH),	and	canine	TT4	 (the	 last	 three	 from	Siemens	
Healthcare	 Diagnostics).	 The	 aim	 was	 to	 include	 immunoassays	
that	are	 frequently	used	 in	 the	veterinary	 laboratory,	and/or	 im‐
munoassays	where	 interference	could	have	a	high	 impact	on	the	
course	of	treatment.
All	analyses	were	carried	out	on	an	automated	chemiluminescent	
system	 (Immulite	 2000;	 Siemens	 Healthineers)	 except	 for	 the	 AMH	
assay,	which	was	performed	manually.	The	AMH	and	canine	TSH	assays	
are	both	noncompetitive	 immunoassays.	The	AMH	assay	 is	an	ELISA	
with	a	pair	of	monoclonal	mouse	antibodies;	one	being	used	for	capture	
and	the	other	for	detection.	The	TSH	assay	is	a	chemiluminescent	en‐
zyme	immunoassay	(CLEIA)	with	a	monoclonal	mouse	antibody	on	the	
solid	phase	and	a	polyclonal	rabbit	antibody	as	the	detection	antibody.
The	progesterone	and	canine	TT4	CLEIAs	are	competitive	assays	
where	the	sample	substances	compete	with	enzyme‐labeled	analytes	
for	 binding	 to	 a	 solid	 phase	 capture	 antibody.	 In	 the	 progesterone	
assay,	the	solid	phase	is	coated	with	a	polyclonal	rabbit	antibody	and	
in	the	canine	TT4	with	a	murine	monoclonal	antibody	(mAb).	All	anal‐
yses	were	performed	according	to	the	manufacturers'	instructions.
2.4 | Selection of samples and prioritization of  
the immunoassay order
To	 evaluate	 if	 anti‐mouse	 antibodies	 are	 a	 source	 of	 erroneous	
results	 in	 the	 AMH	 assay,	 neutered	 dogs	 were	 used,	 seven	 with	
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anti‐mouse	antibodies	detected	using	a	species‐independent	assay1 
and	 seven	 control	 dogs.	A	detectable	AMH	concentration	 in	 neu‐
tered	dogs	with	no	clinical	signs	of	gonadal	tissue	present	according	
to	patient	medical	records	was	considered	evidence	of	interference.
For	PEG	screening,	a	general	order	was	established	to	prioritize	
when	assays	were	run	because	of	varying	sample	volumes:	(a)	AMH;	
(b) TT4;	(c)	TSH;	and	(d)	progesterone.	Samples	were	pretested	in	the	
TSH	and	TT4	 assays	 to	minimize	 the	 risk	of	noninformative	 results	
after	PEG	treatment.	Because	the	TSH	results	were	generally	closer	
to	the	lower	assay	detection	limit	than	the	TT4	results,	only	samples	
with	the	10	highest	TSH	results	were	subsequently	tested	for	inter‐
ference	with	the	PEG	method	in	the	TSH	assay.	The	testing	of	pro‐
gesterone	was	limited	to	intact	female	dogs.	Sample	allocation	to	the	
different	assays	is	summarized	(Table	1).	For	an	overview	of	all	exper‐
iments	and	preparatory	steps,	see	the	attached	flow	chart	(Figure	1).
2.5 | Reduction of interference
Two	 methods	 were	 used	 to	 reduce	 interference;	 blocking	 with	
mouse	IgG	and	PEG	precipitation.
Blocking	with	nonimmune	mouse	IgG	was	used	for	neutered	dogs	
with	detectable	AMH	concentrations.	Heat‐aggregated13	 (MAK33;	
Roche	Molecular	Biochemicals,	Mannheim,	Germany)	and/or	native	
mouse	IgG	(I5381;	Sigma	Aldrich,	St.	Louis,	MO)	was	added	to	the	
samples	 in	 various	 concentrations.	 Heat‐aggregated	 MAK33	 was	
kindly	provided	by	N	Bolstad	(Department	of	Medical	Biochemistry,	
Oslo	University	Hospital).	After	the	addition	of	mouse	IgG,	the	sam‐
ples	were	vortexed	thoroughly	and	incubated	at	4°C	for	30	minutes	
before	analysis.	Dilution	factors	were	applied	as	applicable	for	dif‐
ferent	blocking	concentrations.
In	the	screening	experiment,	PEG	precipitation	was	performed	by	
mixing	one	volume	of	serum	sample	with	one	volume	of	24%	PEG‐6000	
(KEBO	Lab,	Stockholm,	Sweden)	reconstituted	in	0.01	mol/L	PBS,	pH	
7.4	(Sigma	Aldrich).	The	mixture	was	vortexed	and	incubated	at	4°C	
for	 30	minutes,	 followed	 by	 centrifugation	 for	 5	minutes	 at	 9600g 
in	 a	 Heraeus	 Fresco	 17/21	microcentrifuge	 (Thermo	 Fisher,	 Hemel	
Hempstead,	Hertfordshire,	 UK).	 Supernatants	were	 assayed	 or	 dis‐
patched	immediately	to	the	analyzing	laboratory	together	with	the	un‐
treated	samples,	and	a	1:2	dilution	factor	was	applied	for	PEG‐treated	
samples.	This	treatment	was	performed	on	all	samples.
When	the	results	from	samples	treated	with	PEG	and	native	samples	
differed	by	more	than	four	standard	deviations	(SDs)	of	the	intra‐assay	
coefficient	of	variation	(CV)	(Table	2),	the	result	was	considered	to	be	
discrepant.	This	equals	a	99.99%	prediction	interval	for	the	difference.
2.6 | Statistical analysis
In	 the	 screening	 experiment	 with	 PEG,	 differences	 between	 two	
proportions	were	tested	using	a	two‐sample	test	for	equality	of	pro‐
portions	with	continuity	correction.	For	comparisons	involving	more	
than	two	proportions,	a	generalized	 linear	model	was	fitted,	and	a	
Chi‐square	test	was	then	performed	for	H0:p1 = p2 = p3,	and	so	on.	
Pairwise	 post‐hoc	 estimates	 were	 performed	 using	 Tukey's	 range	
test.	All	statistical	analyses	were	performed	with	R	Software	3.3.3	
(R	Core	Team,	Vienna,	Austria).
3  | RESULTS
3.1 | Samples with anti‐mouse antibodies
Twenty‐nine	samples	from	28	dogs	positive	for	anti‐mouse	antibodies	
were	analyzed	in	at	least	one	of	the	immunoassays.	When	submitting	
two	samples	from	the	same	dog,	3	days	elapsed	between	the	samplings.	
TA B L E  1  Assays	tested	on	dogs	with	anti‐mouse	antibodies.	
Descriptive	data	of	sampled	dogs	and	immunoassay	allocation	of	
samples	investigated	for	interference
Breed Age (y) Sex Assays tested
Boxer 6 F AMH,	TT4,	TSH,	
progesterone
Rottweiler 10 F AMH,	TT4,	TSH,	
progesterone
Poodle 12 M AMH,	TT4,	TSH
Miniature	Schnauzer 8 M AMH,	TT4,	TSH
Bernese	Mountain	Dog 7 MN AMH,	TT4,	TSH
Finnish	hound 3 F AMH,	TT4,	
progesterone
Schipperke 5 F AMH,	TSH,	
progesterone
Jack	Russell	Terrier 4 F AMH,	TT4,	
progesterone
Mixed‐breed	dog 1 M AMH,	TT4
German	Shepherd	Dog 4 mo M AMH,	TT4
Shetland	Sheepdog 11 mo M AMH,	TT4
Irish	Terrier 7 M AMH,	TT4
Shetland	Sheepdog 9 F AMH,	TT4
Pug 5 mo F AMH,	TT4
American	Staffordshire	
Terrier
7 M AMH,	TT4
Bearded	Collie 7 M AMH,	TT4
Jagdterrier 9 M AMH,	TSH
Lagotto	Romagnoloa 5 M AMH,	TSH
Bernese	Mountain	Dog 8 FN AMH,	TT4,	TSH
Miniature	Schnauzer 10 FN AMH,	TSH
German	Spaniel 7 F AMH,	progesterone
Papillon 3 MN AMH
Bernese	Mountain	Dog 5 FN AMH
Golden	Retriever 11 M AMH
Mixed‐breed	dog 1 F AMH
Mixed‐breed	dog 9 F AMH
Chihuahua 13 MN AMH
English	Springer	Spaniel 8 FN AMH
Abbreviations:	AMH,	anti‐Müllerian	hormone;	CV,	coefficient	of	
variation;	F,	female;	M,	male;	N,	neutered;	TSH,	thyroid‐stimulating	
hormone;	TT4,	thyroxine.
aTwo	samples	were	submitted	for	this	dog.	
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The	median	age	of	the	dogs	with	anti‐mouse	antibodies	was	7	years,	
IQR	3.75‐9	years.	There	were	11	intact	males,	3	neutered	males,	10	
intact	females,	and	4	neutered	females	of	24	different	breeds.
3.2 | Control samples
Twenty‐five	control	dogs	presenting	22	breeds	were	 included.	There	
were	 four	 intact	 males,	 five	 neutered	males,	 14	 intact	 females,	 and	
two	neutered	females.	The	median	age	was	4	years,	IQR	2.5‐	5	years.	
Breeds	 represented	 included	Labrador	 retriever	 (n	=	3),	Berger	blanc	
Suisse	 (n	=	2),	and	one	each	of	an	Australian	kelpie,	Australian	shep‐
herd,	Border	collie,	Border	terrier,	Cavalier	King	Charles	spaniel,	Cesky	
terrier,	English	cocker	spaniel,	flat‐coated	retriever,	German	shepherd	
dog,	jack	russell	terrier,	Lancashire	heeler,	Lhasa	apso,	malinois,	minia‐
ture	schnauzer,	mixed‐breed,	poodle,	Scottish	terrier,	Sealyham	terrier,	
stabyhoun,	and	vizsla.	All	25	control	sera	were	analyzed	in	all	assays.
3.3 | Effect of anti‐mouse antibodies on the 
result of the AMH assay
Serum	 from	 none	 of	 the	 seven	 neutered	 control	 dogs,	 but	 serum	
from	 two	 of	 seven	 neutered	 dogs	 with	 anti‐mouse	 antibodies	
yielded	detectable	AMH	concentrations.	These	 two	dogs	also	had	
the	 strongest	 anti‐mouse	 reactivity	 of	 the	 seven	 neutered	 dogs	
when	previously	screened	for	interference.
Serum	1	was	from	a	3‐year‐old	male	papillon	that	according	to	
the	medical	records	had	been	neutered	at	another	clinic	29	months	
prior	to	the	collection	of	serum	with	no	surgical	complications.	The	
patient	was	 referred	 to	 the	University	Animal	Hospital	 in	Uppsala	
with	 acute	 gastrointestinal	 signs.	 A	 blood	 test	 revealed	 hypogly‐
cemia	 (2.5	mmol/L,	RI	3.8‐5.8).	After	3	days	of	 intensive	care,	 the	
patient	was	released	from	the	hospital,	free	from	clinical	signs,	and	
with	normalized	glucose	concentrations.
The	 initial	 AMH	 testing	 on	 serum	 1	 yielded	 a	 result	 of	
14.49	 pmol/L.	 Interference	 testing	was	 performed	with	 concentra‐
tions	 of	 0.5	 and	 1.0	 mg/mL	 heat‐aggregated	 MAK33,	 0.5	 mg/mL	
I5381,	and	a	combination	of	0.5	mg/mL	MAK33	+	0.5	mg/mL	I5381	
(Figure	2).	Heat‐aggregated	MAK33	(0.5	mg/mL)	decreased	the	result	
by	22%	(to	11.28	pmol/L),	and	1.0	mg/mL	of	heat‐aggregated	MAK33	
decreased	the	result	by	57%	(to	6.28	pmol/L).	The	greatest	decrease	
(62%)	was	seen	with	the	combination	of	0.5	mg/mL	heat‐aggregated	
MAK33	 +	 I5381	 (to	 5.50	 pmol/L).	 The	 AMH	 concentrations	 were	
below	the	detection	limit	when	the	serum	was	treated	with	PEG.
Serum	2	was	from	a	13‐year‐old	neutered	male	Chihuahua.	The	
owner	sought	medical	care	for	the	dog	after	4	days	of	postprandial	
vomiting.	After	ultrasonographic	examination,	the	primary	suspicion	
was	a	gallbladder	mucocele.	Because	of	the	poor	prognosis,	the	dog	
was	euthanized	1	day	after	admission.
The	initial	AMH	testing	on	serum	2	yielded	a	result	of	5.71	pmol/L.	
The	same	interference	testing	was	performed	as	for	serum	1	(Figure	2).	
Two	treatments	yielded	undetectable	levels	of	AMH;	1.0	mg/mL	heat‐
aggregated	 MAK33	 and	 0.5	 mg/mL	 MAK33	 +	 0.5	 mg/mL	 I5381.	
F I G U R E  1  A	flow	chart	of	the	experiments	covered	in	
this	study.	*Only	samples	with	10	highest	TSH	measurements	
(according	to	pretesting)	were	evaluated.	**Only	intact	females	
were	evaluated.	Abbreviations:	AM,	anti‐mouse	antibodies;	AMH,	
anti‐Müllerian	hormone;	PEG,	polyethylene	glycol;	TSH,	thyroid‐
stimulating	hormone;	TT4,	thyroxine
TA B L E  2   Immunoassay	within‐run	precision.	Within‐run	CVs	
of	assays	investigated	for	interference.	Numbers	are	only	given	
for	the	reference	ranges	that	were	used	in	the	present	study.	The	
in‐house	CVs	were	based	on	duplicate	measurements	of	11	(TT4) or 
10	(TSH)	dogs
Assay Mean %CV %CV99.99%
AMH	(pmol/L)a ≤65.9
66
5.4
3.6
21.7
14.5
Canine	TSH	(µg/L) 0.08 4.4 20
Canine	TT4	(nmol/L) 32.5 5.7 23.4
Progesterone	
(nmol/L)b
0.92‐1.95 8.8 35.3
1.96‐3.23 10.2 40.9
3.24‐7.76 9.7 38.8
7.77‐13.2 7.9 31.7
13.3‐18.1 7 28.1
≥18.2 7 28
Abbreviations:	AMH,	anti‐Müllerian	hormone;	CV,	coefficient	of	varia‐
tion;	TSH,	thyroid‐stimulating	hormone;	TT4,	thyroxine.
aAMH	Gen	II	ELISA	Package	Insert,	2015;1‐6;	Beckman	Coulter	
Diagnostics,	Brea,	CA	92821‐6232.	
bIMMULITE/IMMULITE	2000	Progesterone	Package	Insert,	2013;1‐38;	
Siemens	Healthcare	Diagnostics,	Tarrytown,	NY	10591‐5097.	
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Heat‐aggregated	MAK33	(0.5	mg/mL)	decreased	the	result	by	54%	(to	
2.64	pmol/L)	 and	0.5	mg/mL	 I5381	decreased	 the	adult	by	35%	 (to	
3.71	pmol/L).	The	AMH	concentrations	were	below	the	detection	limit	
when	the	serum	was	treated	with	PEG.
3.4 | Assay screening with PEG
The	 effects	 of	 the	 PEG	 treatments	 are	 summarized	 in	 Table	 3.	 In	
total,	127	paired	analyses	were	performed,	of	which	100	(79%)	re‐
turned	informative	results.
Fifteen	paired	analyses	(native	vs	PEG‐treated	sera)	were	below	
the	 lower	 detection	 limit	 before	 and	 after	 PEG	 treatment.	 Three	
paired	analyses	were	above	 the	upper	detection	 limit	before	PEG	
treatment.	Nine	paired	analyses	carried	out	on	the	Immulite	platform	
returned	the	error	code	“NA”	after	the	PEG	treatment.	Analyses	that	
were	not	within	the	assay	range	before	PEG	treatment	or	that	re‐
turned	an	error	code	after	PEG	treatment	were	not	included	in	the	
analyses.	When	the	post‐PEG	result	was	below	the	assay	range,	the	
lowest	value	was	divided	by	two	for	statistical	calculations.
The	 probability	 of	 getting	 a	 discrepant	 result	 after	 PEG	 treat‐
ment	differed	significantly	depending	on	whether	AMH,	TSH,	TT4,	
or	progesterone	was	analyzed.	This	was	true	for	samples	with	anti‐
mouse	IgG,	without	anti‐mouse	IgG,	and	for	all	samples	(P < 0.001 in 
all	three	cases).	The	presence	or	absence	of	anti‐mouse	antibodies	
did	not	influence	the	probability	of	getting	a	discrepant	result	for	any	
of	the	assays,	except	the	canine	TT4	assay	(P = 0.04).
Five	of	the	29	patient	samples	(17%)	with	anti‐mouse	antibod‐
ies	 did	 not	 have	 discrepant	 results	 in	 any	 of	 the	 immunoassays.	
Conversely,	discrepant	results	were	found	in	at	least	one	of	the	im‐
munoassays	for	all	25	serum	samples	without	anti‐mouse	antibodies.
For	 assay‐specific	 effects	 of	 PEG	 on	 samples	with	 anti‐mouse	
antibodies	and	controls	(See	Figures	3‐6).
4  | DISCUSSION
The	present	 study	evaluated	 if	 anti‐mouse	antibodies,	detected	 in	
a	 species‐independent	 immunoassay,	 were	 a	 source	 of	 erroneous	
F I G U R E  2  Effects	of	polyethylene	glycol	(PEG)	treatment	and	antibody	blocking	on	samples	with	erroneous	anti‐Müllerian	hormone	
(AMH)	results.	For	blocking,	different	concentrations	of	two	mouse	antibodies	(MAK33	and	I5381)	were	used.	The	antibodies	were	also	used	
in	combination	with	0.5	mg/mL	of	each
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results	 in	 the	AMH	assay.	We	also	 assessed	 if	 antibody	precipita‐
tion	with	PEG	could	be	a	practical	tool	for	detecting	antibody	inter‐
ference	in	a	variety	of	immunoassays	used	in	the	clinical	veterinary	
laboratory.
None	of	the	neutered	control	dogs	but	2/7	neutered	dogs	with	
anti‐mouse	IgG	had	detectable	AMH	concentrations.	Out	of	all	neu‐
tered	 dogs	 previously	 screened	 for	 interference,	 these	 two	 dogs	
also	had	the	strongest	reactivity	with	anti‐mouse	IgG.	Immunoassay	
manufacturers	add	neutralizing	 Igs	to	their	sample	 incubation	buf‐
fers,	 which	 serve	 to	 protect	 against	 antibody	 interference,	 which	
is	a	plausible	cause	for	interference	only	occurring	in	samples	with	
the	strongest	reactivity	to	mouse	IgG.	Normal	AMH	concentrations	
for	neutered	dogs	of	both	sexes,	as	measured	with	this	assay,	have	
been	reported	to	be	very	low.2,4,6,14,15	For	neutered	dogs,	this	was	
explained	 by	 the	 absence	 of	 Sertoli	 cells	 in	 males,	 and	 of	 gran‐
ulosa	 cells	 in	 females,	which	are	 the	only	 known	 sources	of	AMH	
in	mammals6,16,17	The	AMH	assay	is	used	for	several	 indications	 in	
dogs,	 including	 diagnosing	 the	 presence	 of	 gonads,2,4‐6,14	 gonadal	
tumors,18,19	and	predicting	 litter	size.20	The	 interferences	found	 in	
the	present	study	might	not	be	a	big	problem	for	diagnosing	tumors,	
as	 granulosa	 and	 Sertoli	 cell	 tumors	 generally	 increase	AMH	con‐
centrations	by	several	magnitudes,18,19	but	they	could	be	misleading	
when	 the	 neutering	 status	 of	 a	 dog	 is	 unknown,	 such	 as	 in	 cases	
of	 suspected	 ovarian	 remnants,	 cryptorchidism,	 or	 for	 stray	 and	
TA B L E  3  A	summary	of	the	polyethylene	glycol	(PEG)	effects.	The	effects	on	hormone	measurements	after	PEG	treatment	for	samples	
with	(mouse:	pos)	and	without	(mouse:	neg)	anti‐mouse	antibodies
AMH TSH TT4 Progesterone Overall
Number	of	discrepancies Mouse:	pos 14/14	(100%) 5/10	(50%) 6/14	(43%) 0/6	(0%) 25/44	(57%)
Mouse:	neg 17/17	(100%) 8/10	(80%) 15/18	(83%) 1/11	(9%) 41/56	(73%)
Median	percentage	of	meas‐
urement	decrease
Mouse:	pos 75% 26% 23% 0*  29%
Mouse:	neg 68% 38% 38% 0*  41%
Abbreviations:	AMH,	anti‐Müllerian	hormone;	CV,	coefficient	of	variation;	neg,	negative;	pos,	positive;	TSH,	thyroid‐stimulating	hormone;	TT4,	
thyroxine
*The	progesterone	measurement	increased	by	1%.	
F I G U R E  3  The	effects	of	polyethylene	glycol	(PEG)	treatment	on	canine	thyroxine	(TT4)	measurements.	Healthy	control	samples	negative	
for	anti‐mouse	IgG	are	to	the	left.	Patient	samples	positive	for	anti‐mouse	IgG	are	to	the	right
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surrendered	dogs	admitted	to	animal	shelters	with	unknown	med‐
ical	histories.	The	 frequency	of	 interference	 in	canine	samples	 for	
the	AMH	Gen	II	assay	is	most	likely	considerably	lower	than	the	9%	
reported	in	the	screening	of	canine	anti‐mouse	antibodies	since	only	
two	of	the	seven	evaluated	samples	caused	erroneous	results.	This	
data	are	consistent	with	larger	cohort	(>10	000	samples)	studies	of	
human	samples	submitted	for	immunoassay	analysis,	which	estimate	
the	frequency	of	interference	to	0.03%‐4%.21‐24
Blocking	with	two	types	of	mouse	IgG	was	used	to	reduce	the	
effect	 of	 interference.	 Blocking	 with	 0.5	 mg/mL	 purified	 mouse	
polyclonal	 IgG	had	 little	 to	no	effect,	 but	0.5	mg/mL	heat‐aggre‐
gated	 MAK33	 decreased	 the	 AMH	 concentrations	 by	 22%	 for	
serum	1	and	54%	for	serum	2.	Increasing	the	MAK33	concentration	
to	1.0	mg/mL	decreased	the	AMH	concentrations	by	57%	for	serum	
1,	and	normalized	the	result	from	5.71	to	<	0.714	pmol/L	in	serum	
2.	Although	the	mechanism	is	not	fully	understood,	aggregated	an‐
tibodies	have	previously	been	shown	to	be	superior	blockers	com‐
pared	with	native	IgG.21	In	the	same	study,	it	was	also	shown	that	
1.0	mg/mL	heat‐aggregated	MAK33	failed	to	normalize	mouse	IgG	
concentrations	in	only	1	out	of	76	human	patient	samples	with	het‐
erophilic	antibodies.	Despite	this	finding,	we	interpreted	the	failure	
of	being	able	to	normalize	serum	1	results	to	be	caused	by	insuffi‐
cient	 blocking	 concentrations	 because	 the	 decrease	 in	 titers	was	
proportional	to	the	concentration	of	MAK33	added.	 Interestingly,	
the	only	other	published	study	assessing	blocking	of	canine	hetero‐
philic	antibodies	showed	that	3.7	mg/mL	of	native	IgG	was	unable	to	
completely	eliminate	antibody	interference,25	which	suggested	that	
higher	IgG	concentrations	might	be	needed	to	neutralize	interfering	
antibodies	in	dogs	compared	with	the	corresponding	antibodies	in	
people.	Both	samples	displayed	linearity	after	serial	dilutions.	High	
AMH	concentrations	could	also	be	caused	by	bilateral	cryptorchi‐
dism,	 but	 the	 explicit	mention	 that	 patient	 1	was	 neutered	 ruled	
out	this	possibility	without	reasonable	doubt,	and	it	would	be	diffi‐
cult	to	explain	the	effects	after	adding	MAK33	for	either	patient	in	
the	absence	of	interfering	antibodies.	After	PEG	treatments,	AMH	
concentrations	in	both	sera	with	erroneous	results	were	below	the	
detection	limit,	but	when	used	for	screening,	the	proportion	of	dis‐
crepant	 results	 did	 not	 differ	 between	 samples	with	 and	without	
anti‐mouse	antibodies	for	any	of	the	immunoassays	studied,	and	a	
very	high	overall	incidence	of	discrepant	results	for	healthy	controls	
(73%)	was	observed.	This	incidence	is	unrealistically	high.	For	sam‐
ples	containing	anti‐mouse	antibodies,	a	57%	incidence	of	interfer‐
ence	might	not	be	out	of	the	question,	but	the	incidence	was	even	
higher	for	samples	that	did	not	contain	any	detectable	anti‐mouse	
antibodies.	It	thus	follows	that	the	PEG	treatment	is	responsible	for	
the	discrepant	results,	but	in	most	cases,	this	is	unlikely	to	be	due	
F I G U R E  4  The	effects	of	polyethylene	glycol	(PEG)	treatment	on	canine	thyroid‐stimulating	hormone	(TSH)	measurements.	Healthy	
control	samples	negative	for	anti‐mouse	IgG	are	to	the	left.	Patient	samples	positive	for	anti‐mouse	IgG	are	to	the	right
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to	interference.	The	most	likely	explanation	for	the	high	number	of	
discrepant	results	obtained	with	the	PEG	method	is	a	significant	co‐
precipitation	of	the	analyte	with	the	Igs.	A	40%	loss	of	TSH	to	PEG	
precipitation	has	been	reported	for	human	samples,	but	the	same	
study	 also	 reported	 stable	 values	 for	 thyroxine	 (TT4).
26	 This	 is	 in	
contrast	to	our	findings,	where	38%	of	both	TSH	and	TT4	were	lost	
in	healthy	controls.	There	was	also	a	major	apparent	co‐precipita‐
tion	of	AMH	(68%	for	controls).	The	progesterone	assay	seemed	to	
be	less	affected	by	co‐precipitation,	as	there	was	a	median	increase	
of	1%	in	progesterone	concentrations	for	the	controls,	and	only	6%	
of	 the	 analyses	 yielded	 discrepant	 results.	 Further	 progesterone	
assay	interference	studies	could	be	warranted	if	the	exact	concen‐
trations	are	used	to	determine	the	optimal	time	for	mating.	Before	
investigating	 interference	 with	 PEG,	 laboratories	 should	 perform	
in‐house	 tests	 for	 specific	 analytes	 on	 control	 sera	 to	 figure	 out	
how	big	a	difference	is	normally	expected	after	PEG	treatment.
An	 extensive	 evaluation	 of	 methods	 for	 removal	 of	 hetero‐
philic	antibodies	in	canine	plasma	was	performed	by	Solter	et	al.25 
Although	the	favored	protocol	was	relatively	 lengthy	and	 involved	
reagents	 that	may	not	be	standard	 in	 laboratories,	 the	preliminary	
results	 were	 encouraging.	 The	 methods	 attempted	 by	 the	 Solter	
group	could	be	preferable	to	those	attempted	by	our	group	 in	the	
present	study,	especially	 if	 the	method	 is	only	 to	be	performed	 in	
a	few	selected	cases.	We	also	saw	promising	results	when	treating	
sera	 that	 had	 erroneous	 AMH	 results	 with	 heat‐aggregated	 IgG.	
However,	this	method	has	to	be	evaluated	more	thoroughly	before	
it	can	be	recommended	to	be	used	for	dog	samples.	This	method	is	
also	 less	convenient	 to	 implement	 in	practice,	because	 immunoas‐
says	 use	 a	 variety	 of	 different	 antibodies,	 and	 the	 blocking	 agent	
is	most	effective	when	it	is	as	similar	as	possible	to	the	tracer	anti‐
body.27	The	fact	that	antibody	interference	occurs	despite	the	fact	
that	most	(if	not	all)	commercial	immunoassay	kits	are	equipped	with	
neutralizing	buffers	suggests	that	certain	interferences	are	quite	dif‐
ficult	 to	block	with	 Ig.	Blocking	solutions	tailored	to	the	particular	
assay	are	 likely	 to	be	superior	 to	commercial	heterophilic	blocking	
reagents	(HBR),	which	contain	multispecies	Igs	that	by	chance	could	
be	 able	 to	 bind	 some	 interfering	 substances.8,28	 Furthermore,	 the	
addition	of	IgG	is	not	likely	to	be	effective	against	interfering	anti‐
bodies	that	bind	the	variable	region	of	the	assay	antibodies,	such	as	
anti‐idiotypic	antibodies,	nor	against	auto‐analyte	antibodies.
Although	 PEG	 treatment	 was	 not	 useful	 in	 detecting	 canine	
antibody	interference,	 interference	caused	by	anti‐mouse	antibod‐
ies	 in	 the	TSH,	TT4,	 and	progesterone	assays	 cannot	be	excluded.	
Theoretically,	the	interference	assay	is	expected	to	predict	interfer‐
ence	more	accurately	for	the	AMH	assay	than	for	any	of	the	other	
tested	assays,	because	they	are	both	noncompetitive	and	based	on	
F I G U R E  5  The	effects	of	polyethylene	glycol	(PEG)	treatment	on	progesterone	measurements.	Healthy	control	samples	negative	for	
anti‐mouse	IgG	are	to	the	left.	Patient	samples	positive	for	anti‐mouse	IgG	are	to	the	right
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mouse	 antibodies.	 The	 detected	 antibodies	 could	 cause	 interfer‐
ence	 in	 the	other	 assays	 to	 a	 lower	extent	because	most	of	 them	
use	 Ig	 from	a	species	other	 than	mouse	 for	capture	and/or	detec‐
tion.	Interfering	antibodies	that	bind	the	constant	region	of	the	assay	
antibodies	can	react	with	a	multitude	of	species,	 including	mouse,	
rabbit,	horse,	sheep,	and	bovine	IgG,29,30	but	with	varying	and	often	
low	affinities,	which	reduces	the	likelihood	of	interference.	The	pro‐
gesterone	and	TT4	assays	use	a	competitive	format,	which	is	less	sus‐
ceptible	 to	 interference	 than	 the	 noncompetitive	 format,31	 unless	
the	antibodies	are	of	high	affinity.32	High‐affinity	antibodies	can	be	
acquired	from	mAb	therapy,	but	mAb	drugs	for	veterinary	use	are	
not	available	in	Sweden.
When	immunoassay	 interference	 is	discussed,	 it	 is	often	pre‐
sumed	that	measurements	are	falsely	increased	(positive	interfer‐
ence).	 However,	 negative	 antibody	 interference	 is	 also	 possible,	
but	less	commonly	observed.	With	the	selection	of	immunoassays	
and	 samples	 used	 in	 this	 study,	 we	 mainly	 anticipated	 positive	
interference.	Samples	positive	 for	anti‐mouse	antibodies	are	de‐
fined	as	such	based	on	their	ability	to	form	a	bridge	between	two	
mouse	antibodies	(positive	interference).	If	these	samples	are	run	
in	 an	 assay	 that	 combines	 a	monoclonal	mouse	 antibody	on	 the	
solid	 phase	with	 a	 detection	 antibody	 raised	 in	 another	 species	
(such	as	the	canine	TSH	assay),	negative	interference	is	possible	if	
only	the	solid	phase	antibody	 is	bound.32	However,	noncompeti‐
tive	assays	are	run	under	reagent	excess	conditions,	meaning	that	
the	concentrations	of	the	assay	antibodies	are	much	higher	than	
normal	 analyte	 concentrations,31	 which	 contributes	 to	 a	 highly	
sensitive	reaction	that	soaks	up	any	antibody‐binding	substances	
in	the	sample,	including	the	intended	analyte.	If	the	anti‐mouse	an‐
tibodies	are	sufficiently	high	in	concentration	and	highly	specific	
(ie,	 iatrogenic	 HAMAs),	 the	 likelihood	 of	 saturating	 the	 binding	
sites	of	the	solid	phase	antibodies	and	causing	negative	 interfer‐
ence	should,	in	theory,	increase.	However,	such	antibodies	are	not	
expected	to	be	present	in	dogs.	Competitive	assays	consisting	of	a	
single	mouse	mAb	on	the	solid	phase	(such	as	the	canine	TT4	assay)	
will	produce	less	signal	in	the	presence	of	anti‐mouse	antibodies,	
but	because	of	 the	 inverse	 relationship	between	signal	and	con‐
centration	in	the	competitive	format,	the	reported	concentrations	
will	be	increased.
Interference	can	also	be	caused	by	cross‐reactivity	due	to	struc‐
tural	similarities	between	the	analyte	and	related	molecules.	Cross‐
reactivity	is	mostly	seen	in	single	antibody‐assays.	Noncompetitive	
assays	that	require	simultaneous	binding	of	an	analyte	to	two	anti‐
bodies	(such	as	the	AMH	assay)	have	a	much	higher	analytical	speci‐
ficity	and	are	less	susceptible	to	crossreactivity.31	The	manufacturer	
states	that	the	AMH	assay	does	not	detect	human	inhibin	A,	activin	
F I G U R E  6  The	effects	of	polyethylene	glycol	(PEG)	treatment	on	anti‐Müllerian	hormone	(AMH)	measurements.	Healthy	control	samples	
were	negative	for	anti‐mouse	IgG	are	to	the	left.	Patient	samples	positive	for	anti‐mouse	IgG	are	to	the	right
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A,	 follicle‐stimulating	 hormone,	 and	 luteinizing	 hormone	 at	 two	
times	 their	physiological	 concentrations.	Equivalent	evaluations	of	
cross‐reacting	canine	proteins	have	not	been	performed.	If	cross‐re‐
acting	substances	were	the	source	of	the	two	false‐positive	results,	
the	concentrations	would	not	be	expected	to	be	depressed	by	the	
addition	of	MAK33.	Although	not	definitively	ruled	out,	cross‐reac‐
tivity	is	therefore	considered	to	be	a	much	less	likely	source	of	inter‐
ference	in	the	AMH	assay.
A	limitation	of	this	study	is	that	the	addition	of	PEG	entails	the	
risk	of	 introducing	dilution	effects	and	volume	inaccuracies,	which	
could	lead	to	discrepancies.	However,	these	problems	are	inherent	
to	this	method	and	to	alternative	methods	such	as	blocking	with	the	
addition	of	nonimmune	antibodies	and	would	still	be	encountered	if	
the	procedure	was	implemented	in	a	laboratory	protocol.
For	a	 laboratory	aiming	to	take	proactive	measures	against	an‐
tibody	interference,	it	would	be	favorable	that	the	same	protocol	is	
used	to	identify	interference	from	a	variety	of	antibodies	in	a	variety	
of	immunoassays.	According	to	our	results,	PEG	treatment	of	canine	
samples	does	not	seem	to	provide	such	a	solution.	However,	it	could	
be	 a	 viable	 option	 for	 identifying	 interference	 in	 cases	where	 the	
analyte	is	not	affected	by	co‐precipitation.
5  | CONCLUSION
Anti‐mouse	antibodies	in	dogs	are	a	source	of	erroneous	AMH	re‐
sults.	Veterinary	clinicians	and	technicians	need	to	be	aware	of	the	
risk	of	immunoassay	interference	from	endogenous	antibodies.	The	
PEG	method	yielded	an	unrealistically	high	rate	of	interference	for	
all	examined	assays,	probably	due	to	co‐precipitation	of	the	analyte.
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